| (Values in U.S. Thousands) | Jun, 2016 | Jun, 2015 | Jun, 2014 | Jun, 2013 | Feb, 2026 |
| Sales | 0 | 30 | 10 | 320 | 0 |
| Sales Growth | -100.00% | +200.00% | -96.88% | unch | unch |
| Net Income | -19,370 | -11,860 | -6,710 | -3,240 | 0 |
| Net Income Growth | -63.32% | -76.75% | -107.10% | unch | unch |
Nexvet Biopharma Ord (NVET)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NexvetBiopharma plc is a biopharmaceutical company. The company is focused on transforming the therapeutic market for companion animals by developing and commercializing novel biologic therapies. Its product candidate consists of NV-01, is a mAb for the control of pain associated with osteoarthritis in dogs, NV-02, is a mAb for the control of pain associated with degenerative joint disease in cats and NV-08, is a receptor fusion protein for the treatment of chronic inflammatory diseases. NexvetBiopharma plc is headquartered in Blackrock, Ireland.
Fiscal Year End Date: 06/30